Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
NZ780253B2 - Methods and materials for GALGT2 gene therapy - Google Patents
[go: Go Back, main page]

NZ780253B2 - Methods and materials for GALGT2 gene therapy - Google Patents

Methods and materials for GALGT2 gene therapy

Info

Publication number
NZ780253B2
NZ780253B2 NZ780253A NZ78025316A NZ780253B2 NZ 780253 B2 NZ780253 B2 NZ 780253B2 NZ 780253 A NZ780253 A NZ 780253A NZ 78025316 A NZ78025316 A NZ 78025316A NZ 780253 B2 NZ780253 B2 NZ 780253B2
Authority
NZ
New Zealand
Prior art keywords
cell
plasmid
cells
raav
galgt2
Prior art date
Application number
NZ780253A
Other versions
NZ780253A (en
Inventor
Paul Taylor Martin
Original Assignee
Research Institute At Nationwide Children's Hospital
Filing date
Publication date
Application filed by Research Institute At Nationwide Children's Hospital filed Critical Research Institute At Nationwide Children's Hospital
Publication of NZ780253A publication Critical patent/NZ780253A/en
Publication of NZ780253B2 publication Critical patent/NZ780253B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01165—N-Acetylneuraminylgalactosylglucosylceramide beta-1,4-N-acetylgalactosaminyltransferase (2.4.1.165)

Abstract

The present disclosure relates to recombinant adeno-associated virus (rAAV) delivery of a GALGT2 polynucleotide. The rAAV comprises a plasmid which comprises a nucleic acid comprising a first AAV2 inverted terminal repeat sequence (ITR), a muscle creatine kinase core promoter sequence, a nucleotide sequence encoding a human GALGT2 polypeptide and a second AAV2 ITR sequence. The disclosure provides rAAV and methods of using the rAAV for GALGT2 gene therapy of neuromuscular disorders. Exemplary neuromuscular disorders include, but are not limited to, muscular dystrophies such as Duchenne muscular dystrophy, Congenital Muscular Dystrophy 1A and Limb Girdle Muscular Dystrophy 2D.

Claims (13)

We claim:
1. A plasmid sing nucleotides 53-2762 of SEQ ID NO: 2.
2. The d of claim 1, wherein said plasmid lacks AAV rep and cap genes.
3. The plasmid of claim 1 or 2, r comprising a selectable marker.
4. An ed cell comprising the plasmid of any one of claims 1-3.
5. The isolated cell of claim 4, wherein the cell is a bacterial cell.
6. A packaging cell comprising the plasmid of any one of claims 1-3, provided that if the cell is a human cell, it is ex vivo.
7. The packaging cell of claim 6 selected from the group consisting of HeLa cells, PerC6 cells, 293 cells, low passage 293 cells, MRC-5 cells, WI-38 cells, Vero cells and FrhL-2 cells.
8. A method of producing a recombinant AAV (rAAV) le comprising contacting a cell with the plasmid of any one of claims 1-3, provided that the method is not performed in a human.
9. The method of claim 8, wherein the cell is the cell of any one of claims 4-7.
10. The method of claim 8 or claim 9, further comprising culturing the cell.
11. The method of any one of claims 10-12, further comprising recovering an rAAV particle from the supernatant of the cell.
12. A recombinant AAV particle produced by the method of any one of claims 8-11.
13. The plasmid of claim 1, substantially as herein described with reference to any one of the examples thereof. 49985PCT_Seqlisting SEQUENCE G <110> Research Institute at Nationwide Children's Hospital <120> METHODS AND MATERIALS FOR GALGT2 GENE Y <130>
NZ780253A 2016-09-16 Methods and materials for GALGT2 gene therapy NZ780253B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562220107P 2015-09-17 2015-09-17
US201562221068P 2015-09-20 2015-09-20
US201662301260P 2016-02-29 2016-02-29
NZ740707A NZ740707B2 (en) 2016-09-16 Methods and materials for galgt2 gene therapy

Publications (2)

Publication Number Publication Date
NZ780253A NZ780253A (en) 2025-06-27
NZ780253B2 true NZ780253B2 (en) 2025-09-30

Family

ID=

Similar Documents

Publication Publication Date Title
IL311713B2 (en) Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
JP7069426B2 (en) Treatment of muscular dystrophy targeting the utrophin gene
JP2017536116A5 (en)
RU2018134295A (en) CLOSED LINEAR DUPLEX DNA FOR NEVIRAL GENE TRANSFER
JP2019519218A5 (en)
JP2011101646A5 (en)
RU2015128098A (en) SYSTEM DESIGN, METHODS AND OPTIMIZED GUIDE COMPOSITIONS FOR MANIPULATION WITH SEQUENCES
IL314884A (en) Methods and materials for gene therapy for beta-4,1-en.-acetylgalactosaminyltransferase 2
JP7440045B2 (en) Nucleic acid-encapsulated AAV hollow particles
JP2024116290A (en) Precisely engineered secret messenger RNA and other polynucleotides
Lkharrazi et al. AAV2 can replicate its DNA by a rolling hairpin or rolling circle mechanism, depending on the helper virus
NZ780253B2 (en) Methods and materials for GALGT2 gene therapy
CN101402945A (en) Process for producing small RNA recombinant birds adeno-associated virus for expression of infectivity resistant bursa of fabricius disease virus
CN105624156A (en) Artificial noncoding RNA containing inverted SINEB2 repetitive sequence and use thereof in enhancement of target protein translation
CN104711240B (en) The application of Avianreovirus σ A albumen and its relevant biological material
US12606845B2 (en) Method for producing nucleic acid-encapsulated AAV hollow particle
CN104762274B (en) The application of Avianreovirus σ NS albumen and its relevant biological material
JP2024519090A5 (en)
EP4667577A1 (en) Itr-rep gene complex
CN118159659A (en) Composition for cell addition
NZ787316B2 (en) Adeno-Associated Virus Vector Delivery of Micro-Dystrophin to Treat Muscular Dystrophy
CN112695032A (en) Promoter pLRRK2 and application thereof
Burnham et al. 556. Analytical ultracentrifugation as an approach to characterize recombinant AAV vectors
WO2025205770A1 (en) Recombinant plasmid containing stuffer dna
EP4522633A2 (en) Adeno-associated viral vectors and uses thereof